Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three…
2 analysts rate CODX Buy on consensus.
Consensus price target: $45.00 (+17409.73% upside from $0.26)
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $622.49K | -84.1% | $-46.9M |
| 2024 | $3.92M | -42.53% | $-37.64M |
| 2023 | $6.81M | -80.09% | $-35.33M |
Stock data for CODX: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics